Expert Operational Team
Fredrik Lehmann
PhD, MBA, Chief Executive Officer
Fredrik Lehmann has held senior executive and operational roles at several biotech companies, including Oncopeptides (Head of Research and CMC), Recipharm (General Manager), and EpiEndo (CEO and CMC). He has also founded several life science companies, including OT Chemistry, which was acquired by Recipharm in 2015. Fredrik Lehmann served as a venture partner at Industrifonden and Entrepreneur in Residence at Sound Bioventures. Fredrik Lehmann has a Ph.D. from the University of Gothenburg and an Executive MBA from the Stockholm School of Economics. In addition, he has published over 50 peer-reviewed articles and 25 patent applications.
Sara Thuresson
MSc Biomedicine, Chief Operating Officer
Sara Thuresson has over 20 years of clinical trial experience from leading positions within CRO, biotech and pharmaceutical companies. She has a Master of Science degree from Karolinska Institutet with part of studies at University of Otago, has received postgraduate training in clinical drug development at Uppsala University and has been awarded the Swedish Diploma in Clinical Trials. Previously, Sara Thuresson has held a variety of positions in clinical drug development at, among others, Guard Therapeutics, Oncopeptides, Wilson Therapeutics, IQVIA and Medivir.
Klara Acs
PhD, Chief Development Officer
Klara Acs brings over 10 years of experience in drug development, having held Associate Principal and Translational Science Director roles at Medivir, Sprint Bioscience, and Oncopeptides. Her expertise spans nonclinical pharmacology, clinical translational science, and real-world evidence generation within Medical Affairs. She holds a PhD in Molecular Biology, completed postdoctoral research at Dartmouth Medical School in the US, and held a Young Faculty position in the Department of Cell and Molecular Biology at Karolinska Institutet.
Antonio
Bermejo Gómez
PhD, Head of CMC (Consultant)
Antonio Bermejo Gómez holds a PhD in Organic Chemistry. He has over 14 years of work experience in the pharmaceutical industry at Sprint Bioscience, Oncopeptides, and Synartro. Antonio Bermejo Gómez is the owner of Abego Pharma Insights AB.
Elisabeth Augustsson
MSc Pharmacy, Head of Regulatory Strategy (Consultant)
Elisabeth Augustsson has extensive experience from executive roles in Regulatory Affairs in pharma and Biotech sector. Owner of Restracom AB.
Sina Saidiakbarzadeh
MSc Pharmacy, QA Advisor CMC (Consultant)
Sina Saidiakbarzadeh has over 10 years Quality Assurance experience within GMP and GDP from both big and small pharma companies. He is owner of Saidi QA Consulting AB.
Peter Gilmour
PhD, Head of Nonclinical Science (Consultant)
Peter Gilmour PhD, DABT, is a nonclinical drug development specialist with 25 years’ experience guiding pharmaceutical programs from drug discovery to market authorization application. He is an expert in nonclinical toxicology and pharmacology, as well as associated regulatory strategy. Throughout his career he has driven nonclinical therapeutic development programs at AstraZeneca and Astellas Pharma. Peter co-founded the toxicology consultancy D2team in 2018.
Board of Directors – world-class excellence in biotech entrepreneurship
Krim Talia
PhD, 3T Invest Founder & Owner, Startups founder & CEO
Chairman of the Board
Dr. Talia holds a PhD from the Stockholm School of Economics and was a Postdoctoral Fellow at the Department of Economics at Harvard University. Dr. Talia has also served as Vice President, Health and Life Science, at RISE – Research Institutes of Sweden. Dr. Talia has extensive experience as a founder and CEO of startups and scaleups such as Nanologica AB and Mindler Group. He has also been CEO at STING, a world-leading incubator and accelerator in Stockholm. Dr. Talia is co-founder of several successful companies in multiple industries. He is the founder and sole owner of 3TInvest, one of Sweden’s most active seed-round investors (including Norrsken Evolve Fund and Pinecone Ventures).
Tobias Larsson Agervald
MD, PhD, Nephrology and Internal medicine specialist
Board member
Dr Agervald holds an MD and PhD from Uppsala University and is a board-certified specialist in internal medicine and nephrology. Dr Agervald is an associate professor and internationally recognized researcher within experimental and clinical nephrology and endocrinology. He performed parts of his PhD studies at Harvard Medical School and a postdoctoral fellowship at Indiana University School of Medicine. Dr Agervald has extensive global drug development experience in both early and later clinical stages, he is CEO at Guard Therapeutics, previously worked as Senior Medical Director at Astellas Pharma Global Clinical Development.
Johan Kördel
PhD, Managing partner at Sound Bioventures,
Board member
Prior to founding Sound Bioventures, Dr. Kördel was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years and led investments and served as a Board Director in companies including: Acacia Pharma (Euronext: ACPH, sold to Eagle Pharmaceuticals), Amplyx (sold to Pfizer), Bonesupport (OMX: BONEX), Celladon (Nasdaq: CLDN), Curzion (sold to Horizon), Reneo Pharma (Nasdaq: RPHM), River Vision (sold to Horizon), Syntaxin (sold to Ipsen), VHSquared (sold to Sorriso Pharma), and Ziarco (sold to Novartis). Dr. Kördel worked in the biopharmaceutical industry for 20 years. He is a co-founder of three biotech companies.
Fredrik Lehmann
PhD, MBA, CEO at Renity Pharma
Board member
Fredrik Lehmann has held senior executive and operational roles at several biotech companies, including Oncopeptides (Head of Research and CMC), Recipharm (General Manager), and EpiEndo (CEO and CMC). He has also founded several life science companies, including OT Chemistry, which was acquired by Recipharm in 2015. Fredrik Lehmann served as a venture partner at Industrifonden and Entrepreneur in Residence at Sound Bioventures. Fredrik Lehmann has a Ph.D. from the University of Gothenburg and an Executive MBA from the Stockholm School of Economics. In addition, he has published over 50 peer-reviewed articles and 25 patent applications.